20 Dec, EOD - Indian

SENSEX 78041.59 (-1.49)

Nifty 50 23587.5 (-1.52)

Nifty Bank 50759.2 (-1.58)

Nifty IT 43771.05 (-2.63)

Nifty Midcap 100 56906.75 (-2.82)

Nifty Next 50 68702.65 (-2.72)

Nifty Pharma 22501.85 (-0.86)

Nifty Smallcap 100 18714.3 (-2.19)

20 Dec, EOD - Global

NIKKEI 225 38701.9 (-0.29)

HANG SENG 19720.7 (-0.16)

S&P 6008.5 (1.05)

Login/Signup

You are Here : Home > Research

30-Oct-2024

Cipla

NP up 15.18%

'On consolidated basis

Quarter ended September 2024 compared with Quarter ended September 2023.

Net sales (including other operating income) of Cipla has increased 5.58% to Rs 7051.02 crore.  Sales of Phamaceuticals segment has gone up 5.01% to Rs 6,775.56 crore (accounting for 95.50% of total sales).  Sales of New Ventures segment has gone up 21.17% to Rs 319.60 crore (accounting for 4.50% of total sales).  Inter-segment sales rose Rs 38.16 crore to Rs 44.14 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 11.38% to Rs 1,804.46 crore.  PBIT of Phamaceuticals segment rose 8.19% to Rs 1,780.73 crore (accounting for 98.68% of total PBIT).  PBIT of New Ventures reported profit of Rs 23.73 crore compared to loss of Rs 25.87 crore.  

PBIT margin of Phamaceuticals segment rose from 25.51% to 26.28%.  PBIT margin of New Ventures segment rose...



Pleaselogin & subscribe to view the full report.

More Reports
More Reports View Company Information

  • Results-Analysis   (30-Oct-2024)

    Cipla

    NP up 15.18%

  • Results-Analysis   (27-Jul-2024)

    Cipla

    OP increased 14.85%

  • Results-Analysis   (13-May-2024)

    Cipla

    OP up 12.11%

  • Results-Analysis   (23-Jan-2024)

    Cipla

    NP up 31.83%